Optimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic Developments
Foghorn Therapeutics (FHTX) has received a new Buy rating, initiated by B.Riley Financial analyst, Kalpit Patel.Invest with Confidence: Follow ...
Foghorn Therapeutics a new buy at B Riley on tumor fighting technology
B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for ...
Yahoo Finance24d
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq ... at the AACR Annual Meeting in April, with partner Lilly,” said Adrian Gottschalk, President and Chief Executive ...
Nasdaq9d
B. Riley Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation
Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with a Buy recommendation. As of January 28, 2025, the average one-year ...
Benzinga.com6d
Foghorn Therapeutics (NASDAQ:FHTX) Stock Quotes, Forecast and News Summary
Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. Foghorn Therapeutics Inc ...
Yahoo Finance27d
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know
Foghorn Therapeutics Inc. (FHTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Yahoo Finance24d
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
Jan. 13, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq ... and KRAS inhibitors will be presented at the AACR Annual Meeting in April, with partner Lilly,” said Adrian Gottschalk, ...